Korelasi antara Skor Ages dan Rekurensi Kanker Tiroid Papiler yang Telah Dilakukan Isthmolobektomi
Keywords:
ekstensi ekstratiroid, isthmolobektomi, kanker tiroid papiler, rekurensi, skor AGESAbstract
Skor AGES (age, grade, extent, size) merupakan sistem stratifikasi prognostik pada kanker tiroid terdiferensiasi, namun perannya dalam memprediksi rekurensi kanker tiroid papiler pasca isthmolobektomi masih diperdebatkan. Penelitian ini bertujuan menilai hubungan antara skor AGES beserta komponennya dengan kejadian rekurensi kanker tiroid papiler pada pasien yang menjalani isthmolobektomi. Penelitian ini merupakan studi analitik observasional retrospektif menggunakan data rekam medis pasien kanker tiroid papiler yang menjalani isthmolobektomi di RSUD Arifin Achmad Provinsi Riau periode 2019–2025. Teknik pengambilan sampel dalam penelitian ini menggunakan metode total sampling. Sebanyak 70 pasien dianalisis, terdiri atas 35 pasien dengan rekurensi dan 35 tanpa rekurensi. Variabel yang diteliti meliputi usia, grade histopatologi, ekstensi tumor, ukuran tumor, skor AGES, dan kejadian rekurensi. Seluruh data diperoleh melalui akses arsip rekam medis dan dokumen pendukung rumah sakit sesuai ketentuan administrasi, kebijakan institusi, dan prinsip kerahasiaan identitas pasien. Analisis statistik dilakukan menggunakan uji bivariat yang sesuai dan regresi logistik biner multivariat menggunakan uji jalur data kategorik. Seluruh sampel memiliki grade histopatologi well-differentiated carcinoma. Analisis bivariat menunjukkan bahwa ekstensi ekstratiroid berhubungan signifikan dengan rekurensi (p = 0,005). Skor AGES juga berhubungan dengan rekurensi pada analisis bivariat. Namun, pada analisis multivariat, hanya ekstensi ekstratiroid yang terbukti sebagai prediktor independen rekurensi (ORa = 0,267; 95% CI: 0,081–0,876; p = 0,029), sedangkan usia, ukuran tumor, dan skor AGES tidak bermakna secara statistik. Skor AGES berhubungan dengan rekurensi pada analisis bivariat, tetapi bukan prediktor independen. Ekstensi ekstratiroid merupakan faktor prognostik independen utama terhadap rekurensi kanker tiroid papiler pasca isthmolobektomi.
References
Addasi, N., Fingeret, A., & Goldner, W. (2020). Hemithyroidectomy for thyroid cancer: A review. Medicina (Kaunas), 56, 586.
Al-Brahim, N., & Asa, S. L. (2006). Papillary thyroid carcinoma: An overview. Archives of Pathology & Laboratory Medicine, 130, 1057–1062.
American Thyroid Association. (2015). ATA guidelines for management of thyroid nodules and differentiated thyroid cancer.
Bai, Y., Kakudo, K., & Jung, C. K. (2020). Updates in the pathologic classification of thyroid neoplasms: A review of the WHO classification. Endocrinology and Metabolism, 35(4), 696–715.
Bavle, R. M. (2013). Orphan Annie-eye nuclei. Journal of Oral and Maxillofacial Pathology, 17, 154–155.
Bongers, P. J., Greenberg, C. A., Hsiao, R., et al. (2020). Differences in long-term quality of life between hemithyroidectomy and total thyroidectomy. Surgery, 167, 94–101.
Bortz, M. D., Kuchta, K., Winchester, D. J., Prinz, R. A., & Moo-Young, T. A. (2021). Extrathyroidal extension predicts negative clinical outcomes in papillary thyroid cancer. Surgery, 169(1), 2–6.
Boucai, L., Zafereo, M., & Cabanillas, M. E. (2024). Thyroid cancer: A review. JAMA, 331, 425.
Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 74(3), 229–263.
Cabanillas, M. E., McFadden, D. G., & Durante, C. (2016). Thyroid cancer. The Lancet, 388, 2783–2795.
Canberk, S., Montezuma, D., Ince, U., et al. (2020). Variants of papillary thyroid carcinoma: An algorithmic cytomorphology-based approach. Acta Cytologica, 64, 288–298.
D’Avanzo, A., Ituarte, P., Treseler, P., & Kebebew, E. (2004). Prognostic scoring systems in follicular thyroid cancer. Thyroid, 14, 453–458.
Davis, N. L., Bugis, S. P., McGregor, G. I., & Germann, E. (1995). Prognostic scoring in follicular thyroid cancer. American Journal of Surgery, 170, 476–480.
Diatmika, I. B. G. T. (2023). Scoring AGES dan AMES pada kanker tiroid terdiferensiasi, asosiasi dengan kekambuhan lokoregional [Tesis, Universitas Gadjah Mada].
Dean, D. S., & Hay, I. D. (2000). Prognostic indicators in differentiated thyroid carcinoma. Cancer Control, 7, 229–239.
Ding, Y., Li, P., Wang, W., et al. (2022). A four-gene signature for predicting overall survival of papillary thyroid cancer. Disease Markers, 8735551.
Dwita, L. F., Rahman, S., & Novianti, H. (2020). Diagnosis dan penatalaksanaan low-risk papillary thyroid carcinoma. Jurnal Kesehatan Andalas, 9, 269–275.
European Society for Medical Oncology. (2022). ESMO clinical practice guidelines: Thyroid cancer.
Fidiawaty, W. A., Selvialiany, S., & Zulfikar, W. (2017). Distribusi keganasan organ tiroid berdasarkan pemeriksaan histopatologi di Kota Pekanbaru. Jurnal Ilmu Kedokteran, 10(2), 132–139.
Gill, K. S., Tassone, P., Hamilton, J., et al. (2016). Thyroid cancer metabolism: A review. Journal of Thyroid Disorders & Therapy, 5, 200.
Gilmartin, A., & Ryan, M. (2018). Incidence of thyroid cancer among patients with thyroid nodules. Irish Medical Journal, 111, 802.
Haddad, R. I., Bischoff, L., Ball, D., et al. (2022). Thyroid carcinoma, version 2.2022, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network, 20, 925–951.
Harahap, W., Tofrizal, T., & Oktahermoniza, O. (2022). Relationship between the expression of BRAF V600E and recurrence of differentiated thyroid cancer. Asian Pacific Journal of Cancer Prevention, 23(11), 3617–3622.
Haugen, B. R., Alexander, E. K., Bible, K. C., et al. (2016). 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 26(1), 1–133.
Hay, I. D. (1990). Papillary thyroid carcinoma. Endocrinology and Metabolism Clinics of North America, 19, 545–576.
Huang, H., Rusiecki, J., Zhao, N., et al. (2019). Age at diagnosis as a prognostic factor in differentiated thyroid cancer: A meta-analysis. Thyroid, 29(6), 784–796.
Iñiguez-Ariza, N. M., & Brito, J. P. (2018). Management of low-risk papillary thyroid cancer. Endocrinology and Metabolism, 33, 185–194.
Ito, Y., Nikiforov, Y. E., Schlumberger, M., & Vigneri, R. (2013). Increasing incidence of thyroid cancer: Controversies explored. Nature Reviews Endocrinology, 9(3), 178–184.
Ito, Y., Miyauchi, A., Kihara, M., et al. (2014). Patient age is significantly related to the progression of papillary thyroid carcinoma. World Journal of Surgery, 38(1), 48–54.
Ito, Y., Miyauchi, A., Kihara, M., et al. (2014). Prognostic significance of extrathyroid extension in papillary thyroid carcinoma. World Journal of Surgery, 38(1), 48–54.
Ito, Y., Miyauchi, A., Kihara, M., et al. (2018). Prognostic factors of papillary thyroid carcinoma: Size, extrathyroid extension, and nodal disease. World Journal of Surgery, 42(7), 2125–2132.
Kaplan, M. M. (1990). Progress in thyroid cancer. Endocrinology and Metabolism Clinics of North America, 19, 469–478.
Kim, B. W., Yousman, W., Wong, W. X., Cheng, C., & McAninch, E. A. (2019). Extent of extrathyroidal extension as a prognostic factor in papillary thyroid carcinoma: A meta-analysis. Thyroid, 29(7), 939–949.
Kim, J., Gosnell, J. E., & Roman, S. A. (2020). Geographic influences in the global rise of thyroid cancer. Nature Reviews Endocrinology, 16(1), 17–29.
Li, M., Dal Maso, L., & Vaccarella, S. (2018). Tumor size and risk of recurrence in papillary thyroid carcinoma: A systematic review and meta-analysis. European Journal of Endocrinology, 178(5), 431–442.
Lim, H., Devesa, S. S., Sosa, J. A., Check, D., & Kitahara, C. M. (2017). Trends in thyroid cancer incidence and mortality in the United States, 1974–2013. JAMA, 317(13), 1338–1348.
Limaiem, F., Rehman, A., & Mazzoni, T. (2024). Papillary thyroid carcinoma. In StatPearls. StatPearls Publishing.
Liu, R., & Xing, M. (2016). TERT promoter mutations in thyroid cancer. Endocrine-Related Cancer, 23(3), R143–R155.
Melo, M., da Rocha, A. G., Vinagre, J., et al. (2017). TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinoma. Journal of Clinical Endocrinology & Metabolism, 102(5), 1522–1531.
Mitchell, A. L., Gandhi, A., Scott-Coombes, D., & Perros, P. (2016). Management of thyroid cancer: UK multidisciplinary guidelines. Journal of Laryngology & Otology, 130(Suppl 2), S150–S160.
Perhimpunan Ahli Bedah Onkologi Indonesia. (n.d.). Pedoman tata laksana kanker tiroid. Jakarta: PerABOI.
Reksoprawiro, S. (2023). Sinopsis bedah kepala leher. Airlangga University Press.
Seib, C. D., & Sosa, J. A. (2019). Evolving understanding of the epidemiology of thyroid cancer. Endocrinology and Metabolism Clinics of North America, 48(1), 23–35.
Steinmüller, T., Klupp, J., Rayes, N., et al. (2000). Prognostic factors in differentiated thyroid carcinoma. European Journal of Surgery, 166, 29–33.
Tuttle, R. M., Leboeuf, R., & Martorella, A. J. (2007). Papillary thyroid cancer: Monitoring and therapy. Endocrinology and Metabolism Clinics of North America, 36, 753–778.
Zhao, Y., Zhang, Y., Liu, X. J., & Shi, B. Y. (2012). Prognostic factors for differentiated thyroid carcinoma. Tumori, 98, 233–237.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Welli Zulfikar, Wirsma Arif Harahap, Dessy Arisanty, Tofrizal Tofriza
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
